119 related articles for article (PubMed ID: 9794237)
1. Mutagenic analysis of Vav reveals that an intact SH3 domain is required for transformation.
Groysman M; Nagano M; Shaanan B; Katzav S
Oncogene; 1998 Sep; 17(12):1597-606. PubMed ID: 9794237
[TBL] [Abstract][Full Text] [Related]
2. Single point mutations in the SH2 domain impair the transforming potential of vav and fail to activate proto-vav.
Katzav S
Oncogene; 1993 Jul; 8(7):1757-63. PubMed ID: 8510922
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine phosphorylation of vav proto-oncogene product containing SH2 domain and transcription factor motifs.
Margolis B; Hu P; Katzav S; Li W; Oliver JM; Ullrich A; Weiss A; Schlessinger J
Nature; 1992 Mar; 356(6364):71-4. PubMed ID: 1531699
[TBL] [Abstract][Full Text] [Related]
4. Vav: Captain Hook for signal transduction?
Katzav S
Crit Rev Oncog; 1995; 6(2):87-97. PubMed ID: 8792085
[TBL] [Abstract][Full Text] [Related]
5. Vav: function and regulation in hematopoietic cell signaling.
Bonnefoy-Bérard N; Munshi A; Yron I; Wu S; Collins TL; Deckert M; Shalom-Barak T; Giampa L; Herbert E; Hernandez J; Meller N; Couture C; Altman A
Stem Cells; 1996 May; 14(3):250-68. PubMed ID: 8724692
[TBL] [Abstract][Full Text] [Related]
6. Vav transformation requires activation of multiple GTPases and regulation of gene expression.
Palmby TR; Abe K; Karnoub AE; Der CJ
Mol Cancer Res; 2004 Dec; 2(12):702-11. PubMed ID: 15634759
[TBL] [Abstract][Full Text] [Related]
7. SH3 domain-dependent interaction of the proto-oncogene product Vav with the focal contact protein zyxin.
Hobert O; Schilling JW; Beckerle MC; Ullrich A; Jallal B
Oncogene; 1996 Apr; 12(7):1577-81. PubMed ID: 8622875
[TBL] [Abstract][Full Text] [Related]
8. An intramolecular SH3-domain interaction regulates c-Abl activity.
Barilá D; Superti-Furga G
Nat Genet; 1998 Mar; 18(3):280-2. PubMed ID: 9500553
[TBL] [Abstract][Full Text] [Related]
9. Introduction of a loss-of-function point mutation from the SH3 region of the Caenorhabditis elegans sem-5 gene activates the transforming ability of c-abl in vivo and abolishes binding of proline-rich ligands in vitro.
Van Etten RA; Debnath J; Zhou H; Casasnovas JM
Oncogene; 1995 May; 10(10):1977-88. PubMed ID: 7539119
[TBL] [Abstract][Full Text] [Related]
10. Distinct expression patterns and transforming properties of multiple isoforms of Ost, an exchange factor for RhoA and Cdc42.
Lorenzi MV; Castagnino P; Chen Q; Hori Y; Miki T
Oncogene; 1999 Aug; 18(33):4742-55. PubMed ID: 10467422
[TBL] [Abstract][Full Text] [Related]
11. Expression of a novel isoform of Vav, Vav-T, containing a single Src homology 3 domain in murine testicular germ cells.
Okumura K; Kaneko Y; Nonoguchi K; Nishiyama H; Yokoi H; Higuchi T; Itoh K; Yoshida O; Miki T; Fujita J
Oncogene; 1997 Feb; 14(6):713-20. PubMed ID: 9038379
[TBL] [Abstract][Full Text] [Related]
12. Isolation and characterization of murine vav2, a member of the vav family of proto-oncogenes.
Schuebel KE; Bustelo XR; Nielsen DA; Song BJ; Barbacid M; Goldman D; Lee IJ
Oncogene; 1996 Jul; 13(2):363-71. PubMed ID: 8710375
[TBL] [Abstract][Full Text] [Related]
13. The proline-rich region of Vav binds to Grb2 and Grb3-3.
Ramos-Morales F; Romero F; Schweighoffer F; Bismuth G; Camonis J; Tortolero M; Fischer S
Oncogene; 1995 Oct; 11(8):1665-9. PubMed ID: 7478592
[TBL] [Abstract][Full Text] [Related]
14. Mutational analysis of the regulatory function of the c-Abl Src homology 3 domain.
Brasher BB; Roumiantsev S; Van Etten RA
Oncogene; 2001 Nov; 20(53):7744-52. PubMed ID: 11753652
[TBL] [Abstract][Full Text] [Related]
15. Vav: a potential link between tyrosine kinases and ras-like GTPases in hematopoietic cell signaling.
Hu P; Margolis B; Schlessinger J
Bioessays; 1993 Mar; 15(3):179-83. PubMed ID: 8489524
[TBL] [Abstract][Full Text] [Related]
16. Critical amino acid substitutions in the Src SH3 domain that convert c-Src to be oncogenic.
Miyazaki K; Senga T; Matsuda S; Tanaka M; Machida K; Takenouchi Y; Nimura Y; Hamaguchi M
Biochem Biophys Res Commun; 1999 Oct; 263(3):759-64. PubMed ID: 10512753
[TBL] [Abstract][Full Text] [Related]
17. The SH3 and SH2 domains are capable of directing specificity in protein interactions between the non-receptor tyrosine kinases cSrc and cYes.
Summy JM; Guappone AC; Sudol M; Flynn DC
Oncogene; 2000 Jan; 19(1):155-60. PubMed ID: 10644991
[TBL] [Abstract][Full Text] [Related]
18. The association of Sam68 with Vav1 contributes to tumorigenesis.
Lazer G; Pe'er L; Schapira V; Richard S; Katzav S
Cell Signal; 2007 Dec; 19(12):2479-86. PubMed ID: 17855053
[TBL] [Abstract][Full Text] [Related]
19. Mechanism of activation of the vav protooncogene.
Coppola J; Bryant S; Koda T; Conway D; Barbacid M
Cell Growth Differ; 1991 Feb; 2(2):95-105. PubMed ID: 2069873
[TBL] [Abstract][Full Text] [Related]
20. v-Rel and c-Rel are differentially affected by mutations at a consensus protein kinase recognition sequence.
Mosialos G; Gilmore TD
Oncogene; 1993 Mar; 8(3):721-30. PubMed ID: 8437855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
